India Pharma Outlook Team | Friday, 29 August 2025
GSK has made known the delivery of its cutting-edge oncology treatment Jemperli (dostarlimab) and Zejula (niraparib) in India, a considerable move to elevate the provision of precision cancer treatments. GSK says that this accomplishment highlights the company’s dedication to the worldwide unmet need for the category of women’s cancer care.
Gynecological cancers are some of the top female cancer types in India. Both endometrial and ovarian cancers have been reported among the top three most common types of cancers from Indian women. It is predicted that by 2045, the occurrence of endometrial cancer in India will raise by 78%, while the number of ovarian cancer cases will go up by 69%.
Jemperli stands as the first and only PD-1 immunotherapy in India which is approved for the treatment of mismatch repair-deficient (dMMR)/microsatellite instability-high (MSI-H) advanced or recurrent endometrial cancer in the second line.
Zejula is the only one that has received approval in India as a PARP inhibitor for first-line monotherapy maintenance treatment regardless of biomarker status in advanced ovarian cancer. It offers a very easy and patient-friendly treatment through its once-daily oral dose.
Also Read: Medical device industry urges review of GST policy
Bhushan Akshikar, Managing Director, GSK India said, "Jemperli and Zejula’s debut is our oncology division’s exit from India with a portfolio of innovation-driven, high-impact therapies targeting a critical unmet need in gynaecological cancers area."
These therapies are based on solid global clinical evidence and have received regulatory approvals in over 40 countries, including the US, the UK, and the EU, and thus, they signify a major advancement in women’s cancer care.
